Topic

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Articles

Emergency action to protect patients and the drug supply may have long-term implications.

Coronavirus Response: Reaction or New Reality?

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

No matter why change may be needed, it is important to comply with all the relevant regulatory requirements, says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.

Embracing Change Management

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Despite increasing R&D budgets by bio/pharma companies, returns on this investment are reducing and the cost of bringing an asset to market is increasing.

The High Price of R&D

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

The Call for a Rapid Response

The promise of new therapies is tempered by the need for affordability, safety, and ethics.

Can Policy Keep Pace with Science and Discoveries?

As a new decade has begun, this editorial reviews some of the biggest, brightest, and boldest happenings from the industry over the past 10 years.

Pharma’s Decade in Brief

Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.

Fighting the Good Fight

As the UK heads to the polls for an unusual December general election, industry issues manifestos on medicines while Europe rejoices some movement … finally.

‘Polling’ All the Way

In batch production, efficient exception management means reducing the time required to identify, review, and resolve process exceptions. Incorporating review by exception functionality within manufacturing execution system (MES) software can streamline biopharmaceutical product release.


Review by Exception: Connecting the Dots

FDA report says drug shortages are underappreciated and patients pay a price.

Viewpoints